ProPhase Labs, Inc.
Close on Oct 19, 2026
- Market cap
- $119.68K
- P/E (TTM)
- –
- Dividend yield
- –
About ProPhase Labs
Pharmaceutical Preparations, SIC 2834
The company operates in biotechnology, personal genomics, and consumer health sectors. Through its genomic testing platforms, it provides direct-to-consumer whole genome sequencing, health and ancestry reporting, and interactive data analysis tools, while also serving academic research institutions. Its therapeutic and diagnostic pipelines focus on pre-cancer screening assays and licensed pharmaceutical compounds undergoing research for oncology and inflammatory conditions. Additionally, the business markets branded herbal supplements formulated to support vitality and wellness.
Operational infrastructure includes clinical laboratory facilities situated in New Jersey and New York, alongside an expanded genomics database incorporating sequencing records from 130 countries. The provided text does not state the company's corporate headquarters location or physical store counts.
Summary of the business section of ProPhase Labs's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ProPhase Labs, Inc.
- Headquarters
- New York, NY
- Address
- 711 Stewart Ave, Suite 200, Garden City 11530
- Phone
- (215) 345-0919
- Employees
- 34, Dec 31, 2024
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Fruci & Associates II, PLLC, Spokane, Washington
Stock & identifiers
- Ticker
- PRPH
- Exchange
- OTC
- Shares outstanding
- 16M, Aug 17, 2026
- Public float
- $15.16M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10.33 reverse, Jun 1, 2026; 1-for-10 reverse, Dec 22, 2025; 2-for-1, Jan 23, 1997
- SEC CIK
- 868278
- CUSIP
- 74345W207
- ISIN
- US74345W2070
- EIN
- 23-2577138
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ted William Karkus | CEO & CHAIRMAN, Director | 3,583,750 |
| Stuart Hollenshead | Chief Operating Officer | – |
| Carolina Abenante | Director | – |
| Louis Gleckel Md | Director | 273,840 |
| Warren Hirsch | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Ted Karkus | $2.12M | $497.20K | $1.77M | $8 | – |
| FY2023 Ted Karkus | $3.37M | $1.92M | $370.70K | $47 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“At December 31, 2024, we employe d 96 full-time employees, of which 52 were engaged in our contract manufacturing operations and 34 employees were employed by other subsidiaries of the Company.”
Corporate history
Events identified from SEC filings